SOUTH
SAN FRANCISCO, Calif., May 15, 2024
/PRNewswire/ -- Researchers from Lund University and Enable Biosciences
announced significant findings from their latest collaborative
study, revealing the superior performance of the automated
multiplex Antibody Detection by Agglutination-PCR (ADAP)
technology over traditional Radiobinding Assays (RBA) in
identifying early stages of Type 1 Diabetes (T1D). The results,
published in eBioMedicine, emphasize the potential for early
detection and intervention in T1D.
The paper may be accessed via
https://www.sciencedirect.com/science/article/pii/S2352396424001798.
The study, part of the Swedish Better Diabetes Diagnosis (BDD)
initiative, compared the efficacy of the ADAP method against the
standard RBA in a comprehensive analysis of Stage 3 T1D among
1-10-year-old children. Samples from over 2500 T1D patients were
compared to an equal number of healthy controls tested to determine
the levels of four islet autoantibodies. ADAP technology not only
met but exceeded the sensitivity and specificity achieved by
traditional RBAs, with specificity of 98% and a sensitivity of 92%
using standardized thresholds, compared to 98% specificity and only
71% sensitivity observed with RBA.
"By integrating ADAP into routine screenings of capillary blood
samples, we can detect and diagnose non-symptomatic type 1 diabetes
earlier, improving patient outcomes and reducing the incidence of
severe complications like diabetic ketoacidosis," said Professor
Åke Lernmark, the study's lead researcher at Lund University. "This technology also
facilitates large-scale screenings with its high throughput
capabilities and minimal blood sample requirements."
ADAP's effectiveness in dual-site automated analysis in
the United States and Sweden underscores its reliability and
adaptability across different laboratory settings. ADAP's capacity
to handle micro-volume samples efficiently makes it particularly
suited for pediatric screenings.
"This breakthrough is a stepping stone towards global efforts in
T1D prevention and management," added Dr. David Seftel, CEO of Enable Biosciences.
The study was generously supported by a grant from The Leona M.
and Harry B. Helmsley Charitable Trust to Lund University and by EU Interreg ÖKS for the
DiaUnion project.
About Enable Biosciences Inc.:
Enable Biosciences Inc. is a leading diagnostic healthcare
company in South San Francisco.
Enable is dedicated to advancing innovative diagnostic solutions
that improve patients' lives by detecting disease when it matters
most. For more information, visit www.enablebiosciences.com.
About Lund University:
Lund University is one of the
world's top universities. The research was conducted at Lund
University Clinical Research Center (CRC) at Skåne University
Hospital in Malmö, Sweden by
researchers from the Department of Clinical Sciences Malmö at
Lund University.
Media Contact:
David Seftel
650-240-3105
377695@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/advanced-screening-method-for-early-detection-of-type-1-diabetes-exceeds-traditional-standards-302145786.html
SOURCE Enable Biosciences, Inc.